NCT06981988View on ClinicalTrials.gov

A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

February 28, 2027

Conditions
Relapsed/Refractory Indolent NHL
Interventions
DRUG

Linperlisib ； Rituximab

Linperlisib ； Rituximab

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY